The HIV Neuropathogenesis Journal Club provides a forum for discussion of seminal papers and cutting-edge research in mechanisms of neuropathogenesis in adult and pediatric HIV, biomarkers for neuro-impairment, and strategies for intervention. The journal club meets bimonthly and is lead by:
Christina M. Marra, MD, Professor, Neurology, Vice Chair (Academic Affairs), Neurology, Adjunct Professor, Medicine (Infectious Diseases), UW
Claudia Crowell, MD, Assistant Professor, Pediatrics, UW
Sarah Benki-Nugent, MS, PhD, Acting Assistant Professor, Global Health, UW
Our next Journal Club will be November 30th at 9:00 AM at 908 Jefferson Street, 13th floor, room 1362.
Articles for Discussion
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. – Veera Venkata Ratnam Bandaru, PhD, Michelle M. Mielke PhD, Ned Sacktor, MD, Justin C. McArthur MBBS, Igor Grant MD, Scott Letendre MD, Linda Chang MD, Valerie Wojna MD, Carlos Pardo MD, Peter Calabresi MD, Sody Munsaka PhD, Norman J. Haughley PhD. Neurology. 2013 Oct 22;81(17):1492-9. doi: 10.1212/WNL.0b013e3182a9565e. Epub 2013 Sep 11
Cerebrospinal fluid metabolomics implicate bioenergetic adaptation as a neural mechanism regulating shifts in cognitive states of HIV-infected patients – Alex M. Dickens, Daniel C. Anthony, Reena Deutsch, Michelle M. Mielke, Timothy D.W. Claridge, Igor Grant, Donald Franklin, Debra Rosario, Thomas Marcotte, Scott Letendre, Justin C. McArthur and Norman J. Haughey. AIDS. 2015 Mar 13;29(5):559-69. doi: 10.1097/QAD.0000000000000580.
A Biological Perspective of CSF Lipids as Surrogate Markers for Cognitive Status in HIV – Norman J. Haughey, Zhu Xiaomao, and Veera Venkata Ratnam Bandaru. J Neuroimmune Pharmacol. 2013 Dec;8(5):1136-46. doi: 10.1007/s11481-013-9506-0. Epub 2013 Nov 8.
Tiraboschi JM, Muñoz-Moreno JA, Puertas MC, Alonso-Villaverde C, Prats A, Ferrer E, Rozas N, Maso M, Ouchi D, Martinez-Picado J, Podzamczer D.Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch. HIV Med. 2015 Jul;16(6):388-92. doi: 10.1111/hiv.12243. Epub 2015 Feb 27.
Ndhlovu LC1, Umaki T, Chew GM, Chow DC, Agsalda M, Kallianpur KJ, Paul R, Zhang G, Ho E, Hanks N, Nakamoto B, Shiramizu BT, Shikuma CM.Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). J Neurovirol. 2014 Dec;20(6):571-82. doi: 10.1007/s13365-014-0279-x. Epub 2014 Sep 17.
Melica G, Canestri A, Peytavin G, et al. Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms. AIDS. 2010 Aug 24;24(13):2130-3.